Home

Avisa Pharma™ Inc. is a development  stage drug/device diagnostic company developing a point of care biomarker BreathTestTM for the rapid, pre-symptomatic detection and monitoring of urease producing pathogens in the lungs.  These bacterial pathogens cause significant morbidity/mortality in patients with Ventilator Associated Pneumonia (VAP), Cystic Fibrosis (CF) and Tuberculosis (TB).  The technology uses detection predominately based upon known virulence factor through the use of stable isotopically labeled compound breath tests for disease inducing pathogens.